Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Buy” by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $19.29.

A number of research firms recently weighed in on REPL. HC Wainwright increased their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th.

Replimune Group Stock Down 1.8 %

REPL stock opened at $13.78 on Thursday. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The firm’s 50-day simple moving average is $12.61 and its 200 day simple moving average is $11.81. The stock has a market cap of $1.06 billion, a PE ratio of -4.49 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts predict that Replimune Group will post -2.96 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several institutional investors have recently made changes to their positions in REPL. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the period. Tower Research Capital LLC TRC raised its position in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after acquiring an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd raised its position in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after acquiring an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Replimune Group during the fourth quarter valued at approximately $117,000. Finally, Quantinno Capital Management LP bought a new position in Replimune Group during the fourth quarter valued at approximately $127,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.